AN ANTINEOPLASTIC DRUG
    104.
    发明公开
    AN ANTINEOPLASTIC DRUG 有权
    抗癌药物

    公开(公告)号:EP1374880A4

    公开(公告)日:2004-04-21

    申请号:EP01274051

    申请日:2001-11-01

    申请人: LI HONGFEN

    发明人: LI HONGFEN

    摘要: The present invention disclosed a novel Antineoplastic drug which is mainly composed of the following Chinese medicinal herbs: Panax ginsing, Poria cocos, Atractylodes macrocephala, Angelic sinensis, Astragalus membranaceus, Curcuma zedoaria, Scutellaria baicalensis, Coptis chinensis, Glycyrrhiza uralensis, Crataegus pinatifida, Hordeum vulgare, Schisandra chinensis, Hedyotis diffusa, Ophiophogon japonicus, and Lobelia chinesis lour. It has been used clinically for 20 years, including 15 years in China and 5 years in Israel. Thousands of tumor patients have taken the antineoplastic drug with 69.7 % of effective rate and 84.3 % in association with radiotherapy and chemotherapy. Clinical and experimental evidence show that it can improve the immunity of organism, inhibit and reverse tumor cells; repose, improve the circulation of blood to inhibit the growth and metastasis of tumor; increase the sensitivity to radiotherapy and chemotherapy and alleviate the toxic and side effect which resulted from them, improve somnus, enhance the appetite, alleviate pain, and protect the function of liver, kidney and ovary; and increase the number of leukocyte and hemoglobin which are reduced by radiotherapy and chemotherapy. It can also enhance the antineoplastic ability of organism, prevent the recurrence of tumor, improve the tumor patient's quality of life and prevent tumorigenesis. The animal tests performed in the University of Telaviv of Israel prove that it can increase the action capacity of NK cells, reduce and prevent the tumor metastasis under stress.